We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 29, 2018

Predictors of Prolonged Benefit With Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant HR+/HER2− Metastatic Breast Cancer

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer in PALOMA-3
Eur. J. Cancer 2018 Nov 01;104(xx)21-31, M Cristofanilli, A DeMichele, C Giorgetti, NC Turner, DJ Slamon, SA Im, N Masuda, S Verma, S Loi, M Colleoni, KP Theall, X Huang, Y Liu, CH Bartlett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading